Forbion overview
Stories about Forbion
Forbion in $450m pharma deal
The sale comes as Forbion is currently attempting to collect €150m for Fund III
Forbion strengthens investor base
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
Forbion strengthens investor base(2)
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
Forbion strengthens investor base
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
Forbion contact information
Offices
Gooimeer 2-35, Naarden, 1411, NetherlandsContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Joy Faucher | Job titleGeneral Partner | LocationNaarden, Netherlands | Email  ----------- |
| Key ContactMr. Alexander Hoffmann | Job titleGeneral Partner | LocationNaarden, Netherlands | Email ----------- |
| Key ContactMr. Robbert Van De Griendt | Job titleGeneral Partner, Investor Relations and Impact | LocationNaarden, Netherlands | Email ----------- |
| Key ContactMs. Rachelle Young | Job titleInvestor Relations Director | LocationNaarden, Netherlands | Email --------- |
Forbion funds managed
Funds in market: 2
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ---------- | Open dateJul 2026 | Strategy --------- | |
Fund size -------- | Open dateJul 2026 | Strategy --------- | |
Closed funds: 19
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size --------- | Close dateOct 2025 | Strategy ------- | |
Fund size --------- | Close dateOct 2024 | Strategy -------- | |
Fund size ---------- | Close dateOct 2024 | Strategy ---------- | |
Stories that mention Forbion
Side Letter: PE's entry barrier; Pictet's double close; Niche index update
Monday is a bank holiday in the UK due to King Charles's coronation this weekend, so Side Letter will return on Tuesday. For now, institutional investors face a knowledge gap when pondering an entry into private markets. Plus: nice news for niche investors. Here’s today's brief, for our valued subscribers only.
Side Letter: Thoma Bravo's timing; PE's job creation credentials; Korea's VC support
Thoma Bravo's apparent eagerness to hit the fundraising trail could prove advantageous at a time when the process is slower-going. Plus: Invest Europe shines a light on PE's job creation credentials; and Korea's government wants to back domestic VCs. Here’s today's brief, for our valued subscribers only.
CHART: The biggest dedicated life sciences capital raisers
Dedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
US steps up as European LPs 'strike’ over Brexit
UK private equity funds are under increased scrutiny from continental investors but US LPs seem to have fewer doubts.
Dutch first-timer reaches halfway mark on €150m fund
Netherlands-based Holland Private Equity has held a €77m interim close on its way to a target of €150m. The firm has also inked its first investment.
ABN AMRO spins out life sciences group
ABN AMRO Capital has spun out its life sciences venture arm, which operates a €200m life sciences fund, focused on the US and Europe.